Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
September 08 2022 - 7:00AM
Business Wire
Agreement supports the development of molecules
targeting acute myeloid leukemia, multiple myeloma, human papilloma
virus (HPV) associated tumors, and additional human leukocyte
antigens (HLAs) that have the potential to increase immunotherapy
options for patients
Selexis SA, a JSR Life Sciences company, and NexImmune Inc.
(Nasdaq: NEXI), a clinical-stage biotechnology company developing
unique approaches to T cell immunotherapies, announced today that
they have signed a service agreement to develop cell lines
targeting rare cancers and autoimmune diseases and to advance two
HLAs that can be used to expand treatments to more patients. Per
the agreement, NexImmune will leverage Selexis’ SUREtechnology
Platform™, a suite of cell line development technologies that
significantly reduce the time, effort, and costs associated with
developing high-performance mammalian cell lines.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220908005135/en/
The Selexis-generated cell lines will be used to manufacture HLA
IgG4 fusion proteins and T cell co-stimulatory monoclonal
antibodies that will be incorporated into NexImmune’s proprietary
AIM injectable nanoparticle modality. These nanoparticles are
designed to be an off-the-shelf injectable modality to engage a
patient’s own T cells to identify and kill a variety of diseased
cells within the body.
“We are pleased to support NexImmune’s exciting programs. Its
innovative T cell modulating nanotechnology has the potential to
create therapies that provide better outcomes for patients
suffering from rare forms of cancer and autoimmune diseases,” said
Mark W. Womack, Chief Executive Officer of Selexis and KBI
Biopharma. “We are excited to continue our longstanding
relationship with NexImmune and are proud to be its cell line
development provider of choice. We look forward to helping advance
their novel immunotherapies to the clinic.”
NexImmune’s off-the-shelf AIM injectable nanoparticles,
decorated with antigen-specific peptides and co-stimulatory
molecules, have the ability to engage antigen-specific T cell
populations at multiple sites in the body and specifically
stimulate or tolerize them to address a range of diseases,
including cancers and autoimmune disorders for which there are
currently no effective cellular therapies available.
“We are thrilled to have a partner in Selexis, as an
industry-leading cell line development provider,” said NexImmune
Chief Scientific Officer, Mathias Oelke. “Our long-established
working relationship made the decision to partner with them again
an easy choice. We look forward to working together as we develop
biologics that have the potential to make a real difference in
patients’ lives.”
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in
cell line development with best-in-class modular technology and
highly specialized solutions that enable the life sciences industry
to rapidly discover, develop and commercialize innovative medicines
and vaccines. Our global client partners have utilized Selexis
technologies to advance more than 160 drug candidates in
preclinical and clinical development and manufacture ten commercial
products. As part of a comprehensive drug development process, the
Company’s technologies shorten development timelines and reduce
manufacturing risks. More information is available at
www.selexis.com
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a
novel approach to immunotherapy designed to employ the body’s own T
cells to generate a specific, potent, and durable immune response.
NexImmune’s lead programs, NEXI-001, NEXI-002 and NEXI-003, are in
Phase 1/2 clinical trials for the treatment of relapsed AML after
allogeneic stem cell transplantation, multiple myeloma refractory
to 3 or more prior lines of therapy and HPV-related cancers,
respectively. NexImmune is also developing AIM nanoparticle
constructs and modalities for potential clinical evaluation in
oncology and in disease areas outside of oncology, including
autoimmune disorders and infectious disease.
The backbone of NexImmune’s approach is a proprietary Artificial
Immune Modulation (AIM™) nanoparticle technology platform. The AIM
technology enables NexImmune to construct nanoparticles that
function as synthetic dendritic cells capable of directing a
specific T cell-mediated immune response. NexImmune’s nanoparticles
employ natural biology to engage, activate and expand endogenous T
cells in ways that combine anti-tumor attributes of
antigen-specific precision, potency and long-term persistence with
reduced potential for off-target toxicities. Alternatively for
autoimmune indications, NexImmune’s nanoparticles can engage
antigen specific autoreactive cells to tolerize or kill cells
responsible for disease without broad immunosuppression. For more
information, visit www.neximmune.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220908005135/en/
Media Inquiries for Selexis Mike Beyer Sam Brown Inc.
mikebeyer@sambrown.com
Company Inquiries for Selexis Maria-Pilar Giménez Associate
Marketing Director Selexis SA maria-pilar.gimenez@selexis.com
NexImmune (NASDAQ:NEXI)
Historical Stock Chart
From Jun 2024 to Jul 2024
NexImmune (NASDAQ:NEXI)
Historical Stock Chart
From Jul 2023 to Jul 2024